Chemotherapy(Cetuximab +irinotecan or cetuximab)
Sponsors
National Cancer Center Hospital
Conditions
Colorectal Cancer
Phase 2
Phase II clinical trial of the third-line Cetuximab and irinotecan or Cetuximab therapy for patients with KRAS wild type unresectable/recurrent colorectal cancer
JPRN-UMIN000001963
Start: 2009-03-01Target: 60Updated: 2026-06-29
Pharmacogenomic analysis for Phase II clinical trial of the third-line Cetuximab and irinotecan or Cetuximab therapy for patients with KRAS wild type unresectable/recurrent colorectal cancer
Active, not recruitingJPRN-UMIN000004507
Start: 2009-03-01Target: 60Updated: 2026-06-29